| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating | 
|---|
 
																	
 
																	
 
																	
 
																	
 
																	One-Year OutlookThe firm expect to achieve a number of value-creating events in the coming year under our cost-efficient busine...
 
																	
 
																	Bone Biologics (NASDAQ:BBLG) reported quarterly losses of $(1.33) per share which missed the analyst consensus estimate of $(0....
 
																	
 
																	Bone Biologics filed a USPTO patent for NELL-1 and announced a $5 million offering to support trials and expand its bone regene...